Momenta Pharmaceuticals, Inc.  

(Public, NASDAQ:MNTA)   Watch this stock  
Find more results for MNTA
11.88
+0.46 (4.03%)
Dec 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.26 - 11.96
52 week 9.38 - 19.90
Open 11.43
Vol / Avg. 282,327.00/547,729.00
Mkt cap 630.24M
P/E     -
Div/yield     -
EPS -2.19
Shares 53.05M
Beta 1.98
Inst. own 84%
Feb 9, 2015
Q4 2014 Momenta Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 1, 2014
Momenta Pharmaceuticals Inc at Deutsche Bank BioFEST
Nov 20, 2014
Momenta Pharmaceuticals Inc at Goldman Sachs US Emerging / SMID Cap Growth Conference
Nov 19, 2014
Momenta Pharmaceuticals Inc at Stifel Healthcare Conference
Nov 12, 2014
Momenta Pharmaceuticals Inc at Credit Suisse Healthcare Conference
Nov 5, 2014
Q3 2014 Momenta Pharmaceuticals Inc Earnings Call - Webcast
Nov 5, 2014
Q3 2014 Momenta Pharmaceuticals Inc Earnings Release
Oct 10, 2014
Momenta Pharmaceuticals Inc 2014 R&D Day - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -311.71% -305.68%
Operating margin -313.57% -309.01%
EBITD margin - -285.89%
Return on average assets -45.84% -29.97%
Return on average equity -54.84% -34.40%
Employees 269 -
CDP Score - -

Address

675 West Kendall Street
CAMBRIDGE, MA 02142
United States - Map
+1-617-4919700 (Phone)
+1-617-6210431 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Momenta Pharmaceuticals, Inc. (Momenta) is a biotechnology company specializing in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). This results in a diversified product pipeline of complex generic, follow-on biologic (FOB) and novel drugs. The Company�s complex generic programs target marketed products, which were originally approved by the United States Food and Drug Administration (FDA) as New Drug Applications (NDAs). Its M356, is designed to be a generic version of Copaxone (glatiramer acetate injection), a drug that is indicated for the reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis (RRMS). During the year ended December 31, 2011, it acquired the assets of Virdante. On February 13, 2012 it entered into a global collaboration (Baxter Agreement) with Baxter International Inc.

Officers and directors

James R. Sulat Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Craig A. Wheeler President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard P. Shea Chief Financial Officer, Senior Vice President
Age: 62
Bio & Compensation  - Reuters
Michael Franken M.D. President - Biosimilars Business, Senior Vice President
Age: 49
Bio & Compensation  - Reuters
Ganesh Venkataraman Kaundinya Ph.D. Senior Vice President - Research, Chief Scientific Officer
Age: 47
Bio & Compensation  - Reuters
Bruce A. Leicher Esq. Senior Vice President, General Counsel, Secretary
Age: 58
Bio & Compensation  - Reuters
John E. Bishop Ph.D. Senior Vice President - Pharmaceutical Sciences
Age: 52
Bio & Compensation  - Reuters
James M. Roach M.D. Senior Vice President - Development, Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
John K. Clarke Independent Director
Age: 60
Bio & Compensation  - Reuters
Bruce L. Downey Independent Director
Age: 66
Bio & Compensation  - Reuters